全文获取类型
收费全文 | 80009篇 |
免费 | 4359篇 |
国内免费 | 175篇 |
专业分类
耳鼻咽喉 | 967篇 |
儿科学 | 1776篇 |
妇产科学 | 1662篇 |
基础医学 | 10766篇 |
口腔科学 | 3024篇 |
临床医学 | 6245篇 |
内科学 | 19653篇 |
皮肤病学 | 1798篇 |
神经病学 | 7059篇 |
特种医学 | 1885篇 |
外科学 | 10524篇 |
综合类 | 370篇 |
一般理论 | 33篇 |
预防医学 | 7041篇 |
眼科学 | 1490篇 |
药学 | 5500篇 |
中国医学 | 297篇 |
肿瘤学 | 4453篇 |
出版年
2024年 | 49篇 |
2023年 | 483篇 |
2022年 | 285篇 |
2021年 | 1215篇 |
2020年 | 735篇 |
2019年 | 1308篇 |
2018年 | 2419篇 |
2017年 | 1560篇 |
2016年 | 1628篇 |
2015年 | 2183篇 |
2014年 | 2271篇 |
2013年 | 3242篇 |
2012年 | 6992篇 |
2011年 | 7200篇 |
2010年 | 3232篇 |
2009年 | 2353篇 |
2008年 | 6063篇 |
2007年 | 6260篇 |
2006年 | 6217篇 |
2005年 | 5989篇 |
2004年 | 5436篇 |
2003年 | 4956篇 |
2002年 | 4693篇 |
2001年 | 1609篇 |
2000年 | 2110篇 |
1999年 | 1050篇 |
1998年 | 264篇 |
1997年 | 196篇 |
1996年 | 198篇 |
1995年 | 181篇 |
1994年 | 142篇 |
1993年 | 139篇 |
1992年 | 147篇 |
1991年 | 134篇 |
1990年 | 82篇 |
1989年 | 95篇 |
1988年 | 63篇 |
1987年 | 59篇 |
1986年 | 75篇 |
1985年 | 86篇 |
1984年 | 114篇 |
1983年 | 74篇 |
1982年 | 100篇 |
1981年 | 83篇 |
1980年 | 89篇 |
1979年 | 48篇 |
1978年 | 46篇 |
1977年 | 41篇 |
1976年 | 40篇 |
1974年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
José Ramón Cansino Alcaide Luis Martínez-Piñeiro 《Clinical & translational oncology》2006,8(3):148-152
Summary Genes involved in cancer generation are usually tumor suppressors and oncogenes. Progressive genetic alterations in these
genes are involved in the mechanisms of tumorigenesis. In prostate cancer, additionally several chromosomal loci that should
harbor mutated genes have been proposed. Some genes have been found altered in prostate cancer, such as PTEN, TP53, AR, RNASEL
(HPC1), ELAC2 (HPC2), CDKN2A and MSR1 and those can be natural targets for new strategies of treatment. Besides, gene therapy
has been suggested to be suitable for prostate cancer treatment. This approach includesex vivo corrective therapy, suicide, and antisense therapy. 相似文献
82.
83.
André H. Eriksson Manthena V.S. Varma Everett J. Perkins Cheryl L. Zimmerman 《Journal of pharmaceutical sciences》2010,99(3):1574-1581
LY354740 is a potent mGlu2/3 agonist with a limited oral bioavailability. Its alanyl prodrug, LY544344, showed high affinity to the intestinal peptide transporter PEPT1, and improved the oral bioavailability of LY354740 in various animal models. The aim of the present study was to investigate the mechanism of in vivo absorption of the dipeptidic prodrug LY544344. The permeabilities of LY544344 and LY354740 were examined in the rat in situ single‐pass intestinal perfusion model. The intestinal absorptive flux of LY354740 was shown to be very low in comparison with LY544344. The absorptive flux of LY544344 could best be described by a Michaelis–Menten process in parallel with a linear process. The estimated parameters were: Jmax = 26.7 × 10?5 µmol/(cm2‐s), Km = 2.6 mM. The absorptive permeability of LY544344 was reduced to approximately 5% of control in the presence of excess Gly‐Sar, a known PEPT1 substrate. Intracellular accumulation of LY354740 and LY544344, estimated postperfusion, showed high levels of LY354740 over LY544344 at all perfusate concentrations studied. However, there was a decline in the intracellular ratio of LY354740 to LY544344 at higher concentrations, suggesting that the metabolic activation to release LY354740 is saturable. © 2009 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 99: 1574–1581, 2010 相似文献
84.
85.
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. 总被引:3,自引:0,他引:3
Pavel Sova Xiao-Wei Ren Shaoheng Ni Kathrin M Bernt Jie Mi Nancy Kiviat André Lieber 《Molecular therapy》2004,9(4):496-509
We have constructed a new capsid-modified adenovirus (Ad) vector that specifically replicates in tumor cells and expresses TNF-related apoptosis-inducing ligand (TRAIL). The Ad capsid contains short-shafted fibers derived from Ad serotype 35, which allow for efficient infection of malignant tumor cells, and largely avoids innate toxicity after intravenous application. Replication-dependent homologous recombination in Ad genomes was used to achieve tumor-specific expression of Ad E1a (to mediate viral replication) and TRAIL (to mediate apoptosis and enhance release of progeny virus from infected cells). We demonstrated that our oncolytic vector (Ad5/35.IR-E1A/TRAIL) induced apoptosis in human tumor cell lines derived from colorectal, lung, prostate, and liver cancer. Both in vitro and in vivo tumor models showed efficient intratumoral spread of this vector. In a model for metastatic colon cancer, tail vein infusion of Ad5/35.IR-E1A/TRAIL resulted in elimination of preestablished liver metastases. Intravenous injection of this vector caused a transient elevation of serum glutamic pyruvic transaminase in tumor-bearing mice, which we attributed to factors released from apoptotic tumor cells. Liver histology analyzed at day 14 after virus injection did not show signs of hepatocellular damage. This new oncolytic vector represents a potentially efficient means for gene therapy of metastatic cancer. 相似文献
86.
Aldo Cunha Medeiros Irami Araújo Filho Vítor Brasil Medeiros Laíza Araújo Mohana Pinheiro Flávio Henrique Miranda Araújo Freire Italo Medeiros Azevedo José Brand?o-Neto 《Journal of investigative surgery》2007,20(1):41-48
After total gastrectomy, the ileocecal graft may act as a reservoir and protect against reflux but give rise to transposition of the ileum and cause possible changes in bile acid metabolism and nutrition. This study compared the ileocecal graft and jejunal pouch. Male Wistar rats weighing 265 +/- 22 g were submitted to sham operation (S), ileocecal interposition graft (IIG), and jejunal pouch interposition graft (JP) after total gastrectomy. Eight weeks later, the esophagus was examined for evidence of esophagitis. Nutritional biochemistry and weight profile were documented preoperatively and 8 weeks after surgery. The oral glucose tolerance test was performed. Thirty-three rats were operated on and 30 survived for 8 weeks. Esophagitis occurred in seven JP rats. Body weight was significantly higher in IIG than in JP rats (p < .05). Normal glucose tolerance to intragastric glucose load was observed in sham and operated rats. JP rats had a significant decrease in serum albumin, glucose, transferrin, hemoglobin, iron, folate, and calcium, compared to sham (p < .05). Cobalamine was significantly lower in IIG rats than in JP rats (p < .05). In the IIG and JP groups, serum/hepatic total bile acid did not differ significantly from preoperative and sham values. In conclusion, the IIG interposition graft in rats prevented esophagitis, preserved nutrition, and did not interfere with enterohepatic total bile acid circulation. 相似文献
87.
Defective implant osseointegration under protein undernutrition: prevention by PTH or pamidronate. 总被引:1,自引:0,他引:1
Romain Dayer Isabelle Badoud René Rizzoli Patrick Ammann 《Journal of bone and mineral research》2007,22(10):1526-1533
Protein deficiency is associated with impaired titanium osseointegration. We studied whether systemic treatment with PTH or pamidronate could influence the resistance to pull-out of titanium rods implanted into rats proximal tibia under normal and isocaloric low protein intake. PTH or pamidronate prevented the deleterious effects of protein undernutrition on bone microarchitecture close to the implant and on mechanical fixation. PTH even significantly improved implant osseointegration. INTRODUCTION: Protein deficiency is highly prevalent among elderly patients hospitalized in orthopedic wards. Reduced protein intake impairs titanium osseointegration in rats. Whether stimulator of bone formation or inhibitor of bone resorption could improve implant osseointegration under protein deprivation is not known. We studied the effects of systemic treatment with PTH or pamidronate on the resistance to pull-out of titanium rods implanted into rats proximal tibia under normal and isocaloric low protein intake. MATERIALS AND METHODS: We measured the resistance to pull-out 1-mm-diameter titanium rods implanted into the proximal tibias of 49 adult female rats receiving a normal or an isocaloric low protein diet. After 2 wk on either diet, the implants were inserted, and the rats received PTH(1-34), pamidronate or saline vehicle for 8 wk. The tibias were removed for microCT morphometry, followed by the evaluation of pull-out strength. RESULTS: Pull-out strength was lower in rats fed an isocaloric low protein diet compared with rats fed a normal protein intake (-29%). PTH and pamidronate significantly increased pull-out strength in animals fed a normal or a low protein diet, the effect of PTH being of higher magnitude. The PTH- or pamidronate-mediated increase in pull-out strength was associated with significant increases of relative bone volume, bone-to-implant contact, and trabecular thickness, whereas trabecular spacing was reduced, in the vicinity of the implants. CONCLUSIONS: We confirmed that isocaloric low protein intake impairs titanium implant osseointegration. PTH or pamidronate prevented the deleterious effects of protein undernutrition and even significantly improved the implant osseointegration. These results indicate that systemic administration of PTH or pamidronate could be considered for preventing uncemented arthroplasty loosening in protein undernourished patients. 相似文献
88.
89.
Jacobo E Mintzer Larry E Tune Christopher D Breder René Swanink Ronald N Marcus Robert D McQuade Andy Forbes 《The American journal of geriatric psychiatry》2007,15(11):918-931
OBJECTIVE: To assess the efficacy and safety of aripiprazole for psychosis associated with Alzheimer dementia (AD). METHODS: In this double-blind, multicenter study, 487 institutionalized patients with psychosis associated with AD were randomized to placebo or aripiprazole, 2, 5 or 10 mg/day. Primary efficacy assessment was the mean change from baseline to week 10 on the Neuropsychiatric Inventory-Nursing Home (NPI-NH) version Psychosis Subscale score. Secondary measures included NPI-NH Total, Clinical Global Impression-Severity of Illness (CGI-S), Brief Psychiatric Rating Scale (BPRS) Core and Total, and the Cohen-Mansfield Agitation Inventory (CMAI) scores. RESULTS: Aripiprazole 10 mg/day showed significantly greater improvements (mean change [2 x SD]) than placebo on the NPI-NH Psychosis Subscale (-6.87 [8.6] versus -5.13 [10.0]; F = 6.29, df = 1, 422, p = 0.013 by analysis of covariance [ANCOVA]); CGI-S (-0.72 [1.8] versus -0.46 [1.6]; F = 4.68, df = 1, 419, p = 0.031 [ANCOVA]); BPRS Total (-7.12 [18.4] versus -4.17 [21.6]; F = 4.72, df = 1, 399, p = 0.030 [ANCOVA]); BPRS Core (-3.07 [6.9] versus -1.74 [7.8]; F = 7.30, df = 1, 407, p = 0.007 [ANCOVA]); CMAI (-10.96 [22.6] versus -6.64 [28.6]; F = 5.23, df = 1, 410, p = 0.023 [ANCOVA]), and NPI-NH Psychosis response rate (65 versus 50%; chi(2) = 5.52, df = 1, p = 0.019 [CMH]). Aripiprazole 5 mg/day showed significant improvements versus placebo on BPRS and CMAI scores. Aripiprazole 2 mg/day was not efficacious. Cerebrovascular adverse events were reported: aripiprazole 2 mg/day, N = 1; 5 mg/day, N = 2; 10 mg/day, N = 4; placebo, N = 0. No deaths in any group (aripiprazole 2 mg/day, 3%; 5 mg/day, 2%; 10 mg/day, 7%; placebo, 3%) were considered to be treatment-related. CONCLUSION: Aripiprazole 10 mg/day was efficacious and safe for psychosis associated with AD, significantly improving psychotic symptoms, agitation, and clinical global impression. However, clinicians should be aware of the safety considerations of atypical antipsychotic uses in this population. 相似文献
90.